摘要

Idiopathic pulmonary fibrosis (IPF), a chronic and progressive fibrosing interstitial pneumonia, is a fatal lung disease with a median survival time of 3-5 years. Problems in accurate diagnosis, poor prognosis, limited clinical therapy, and high mortality rate together demonstrate that the development of efficient therapeutic strategies for IPF is an important future endeavor. Deeper understanding of pathogenesis and identification of biomarkers and pathways involved might lead in the future to the emergence of some agents as novel therapeutics for IPF. This review article presents the pathogenesis, therapeutic interventions, treatment approaches, and strategies employed for the design of antifibrotic agents for the treatment of IPF along with the patent literature from the past 10 years. With a dozen antifibrotic agents possessing exciting preclinical potential in the armory, it seems certain that some of them will advance to clinical stage investigations. The results of clinical trials for some of the new agents are also awaited to assess their benefits in terms of efficacy and survival benefits.
原文英語
頁(從 - 到)527-553
頁數27
期刊Journal of Medicinal Chemistry
60
發行號2
DOIs
出版狀態已發佈 - 一月 26 2017

指紋

Idiopathic Pulmonary Fibrosis
Literature
Patents
Interstitial Lung Diseases
Therapeutics
Lung Diseases
Biomarkers
Clinical Trials
Mortality

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

引用此文

@article{96065e404e0a4cc6a6211d1dc5212b2b,
title = "Idiopathic pulmonary fibrosis: Current status, recent progress, and emerging targets",
abstract = "Idiopathic pulmonary fibrosis (IPF), a chronic and progressive fibrosing interstitial pneumonia, is a fatal lung disease with a median survival time of 3-5 years. Problems in accurate diagnosis, poor prognosis, limited clinical therapy, and high mortality rate together demonstrate that the development of efficient therapeutic strategies for IPF is an important future endeavor. Deeper understanding of pathogenesis and identification of biomarkers and pathways involved might lead in the future to the emergence of some agents as novel therapeutics for IPF. This review article presents the pathogenesis, therapeutic interventions, treatment approaches, and strategies employed for the design of antifibrotic agents for the treatment of IPF along with the patent literature from the past 10 years. With a dozen antifibrotic agents possessing exciting preclinical potential in the armory, it seems certain that some of them will advance to clinical stage investigations. The results of clinical trials for some of the new agents are also awaited to assess their benefits in terms of efficacy and survival benefits.",
author = "Liu, {Yi Min} and Kunal Nepali and Liou, {Jing Ping}",
year = "2017",
month = "1",
day = "26",
doi = "10.1021/acs.jmedchem.6b00935",
language = "English",
volume = "60",
pages = "527--553",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "2",

}

TY - JOUR

T1 - Idiopathic pulmonary fibrosis

T2 - Current status, recent progress, and emerging targets

AU - Liu, Yi Min

AU - Nepali, Kunal

AU - Liou, Jing Ping

PY - 2017/1/26

Y1 - 2017/1/26

N2 - Idiopathic pulmonary fibrosis (IPF), a chronic and progressive fibrosing interstitial pneumonia, is a fatal lung disease with a median survival time of 3-5 years. Problems in accurate diagnosis, poor prognosis, limited clinical therapy, and high mortality rate together demonstrate that the development of efficient therapeutic strategies for IPF is an important future endeavor. Deeper understanding of pathogenesis and identification of biomarkers and pathways involved might lead in the future to the emergence of some agents as novel therapeutics for IPF. This review article presents the pathogenesis, therapeutic interventions, treatment approaches, and strategies employed for the design of antifibrotic agents for the treatment of IPF along with the patent literature from the past 10 years. With a dozen antifibrotic agents possessing exciting preclinical potential in the armory, it seems certain that some of them will advance to clinical stage investigations. The results of clinical trials for some of the new agents are also awaited to assess their benefits in terms of efficacy and survival benefits.

AB - Idiopathic pulmonary fibrosis (IPF), a chronic and progressive fibrosing interstitial pneumonia, is a fatal lung disease with a median survival time of 3-5 years. Problems in accurate diagnosis, poor prognosis, limited clinical therapy, and high mortality rate together demonstrate that the development of efficient therapeutic strategies for IPF is an important future endeavor. Deeper understanding of pathogenesis and identification of biomarkers and pathways involved might lead in the future to the emergence of some agents as novel therapeutics for IPF. This review article presents the pathogenesis, therapeutic interventions, treatment approaches, and strategies employed for the design of antifibrotic agents for the treatment of IPF along with the patent literature from the past 10 years. With a dozen antifibrotic agents possessing exciting preclinical potential in the armory, it seems certain that some of them will advance to clinical stage investigations. The results of clinical trials for some of the new agents are also awaited to assess their benefits in terms of efficacy and survival benefits.

UR - http://www.scopus.com/inward/record.url?scp=85010702184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010702184&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.6b00935

DO - 10.1021/acs.jmedchem.6b00935

M3 - Review article

C2 - 28122457

AN - SCOPUS:85010702184

VL - 60

SP - 527

EP - 553

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 2

ER -